Quest for the right Drug
דאלאצין סי 150 מ"ג/מ"ל DALACIN C 150 MG/ML (CLINDAMYCIN PHOSPHATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי, תוך-שרירי : I.V, I.M
צורת מינון:
תמיסה להזרקה : SOLUTION FOR INJECTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Posology : מינונים
4.2 Posology and method of administration Posology Parenteral (IM or IV administration). Dalacin® C (clindamycin phosphate) must be diluted prior to IV administration and should be infused over at least 10-60 minutes. Adults: Serious infections: 600 mg - 1.2 g/day in two, three or four equal doses. More severe infections: 1.2-2.7 g/day in two, three or four equal doses. Single IM injections of greater than 600 mg are not recommended nor is administration of more than 1.2 g in a single one-hour infusion. For more serious infections, these doses may have to be increased. In life-threatening situations, doses as high as 4.8 g daily have been given intravenously to adults. Alternatively, the drug may be administered in the form of a single rapid infusion of the first dose followed by continuous IV infusion. Paediatric population Children (over 1 month of age): Serious infections: 15-25 mg/kg/day in three or four equal doses. Clindamycin should be dosed based on total body weight regardless of obesity. More severe infections: 25-40 mg/kg/day in three or four equal doses. In severe infections it is recommended that children be given no less than 300 mg/day regardless of body weight. Elderly patients: The half-life, volume of distribution and clearance, and extent of absorption after administration of clindamycin phosphate are not altered by increased age. Analysis of data from clinical studies has not revealed any age-related increase in toxicity. Dosage requirements in elderly patients should not be influenced, therefore, by age alone. See Precautions for other factors which should be taken into consideration Dosage in renal/hepatic impairment: Clindamycin dosage modification is not necessary in patients with renal or hepatic insufficiency. The concentration of clindamycin in diluent for infusion should not exceed 18 mg per ml and INFUSION RATES SHOULD NOT EXCEED 30 MG PER MINUTE. The usual infusion rates are as follows: Dose Diluent Time 300 mg 50 ml 10 min 600 mg 50 ml 20 min 900 mg 50-100 ml 30 min 1200 mg 100 ml 40 min
שימוש לפי פנקס קופ''ח כללית 1994
התרופה תימצא רק בבתי חולים ותנופק לחולים אמבולטורים רק באמצעותם
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה אשפוזית לפי החלטת משרד הבריאות
מידע נוסף